Bifidobacterium breve
Bifidobacterium breve has been studied in 9 papers since 2022: 2 trials in people, 1 in animals, 1 in cells, 5 reviews; 4 in the past year. Its furthest trials in people are at early phase 1. The newest paper, Oct 22, 2026: “Targeting the gut-brain axis with Bifidobacterium breve in neurodegeneration: A comprehensive narrative review of current evidence in…”.
1 new paper in 30 daysSee all 9 papers on bifidobacterium breve
At a glance
The findings reach people, from one lab or study. 2 independent labs in 2 countries; 1 trial, none about aging, 1 with no results posted.
“There were no marked changes in the overall composition of the gut microbiota by the probiotic supplementation.”
1 of its findings points the other way.
- 2 independent labs in 2 countries
- 1 finding against
- 1 trial, none about aging, 1 with no results posted
- Funders: Morinaga Milk Industry and 8 more
- 10 of 10 findings with company ties
- Human trial2
- Model organisms1
- Cells1
Studies in people
2 studies gave bifidobacterium breve to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
no change: Has no effect on knee extension strength no change: Has no effect on microbiome | Randomized trial24 weeks | 50 peopleBothapproximately 80 yearsPatients with sarcopenia | Nutrients, Sep 20, 2026 |
no change: Has no effect on cognitive function down: Decreases brain atrophy no change: Has no effect on microbiome | Randomized trial24 weeks | 130 people65–89 yearsOlder adults with suspected MCI | Journal of Alzheimer's disease : JAD, Jan 1, 2022 |
What did studies of bifidobacterium breve find?
8Studies of bifidobacterium breve measured 8 outcomes, among them cognitive function, microbiome and microbiome composition.
Cognitive function
upin humans2no changein humans1
2 studies
Cognitive function
upin humans2no changein humans1
Bifidobacterium breve showed no clear effect on cognitive function in FAS at week 24.
Human trialin FAS at week 2424 weeksn = 115
Bifidobacterium breve improves cognitive function in humans.
Human trialprobiotic strain Bifidobacterium breve MCC1274 (A1)24 weeksn = 115
Bifidobacterium breve improves cognitive function in humans (at risk for Alzheimer's disease).
Reviewat risk for Alzheimer's disease
Microbiome
no changein humans2
2 studies
Microbiome
no changein humans2
Bifidobacterium breve showed no clear effect on microbiome in humans.
Human trial24 weeksn = 50
Bifidobacterium breve showed no clear effect on microbiome in humans.
Human trialfeces24 weeksn = 130
Microbiome composition
no changein humans2
2 studies
Microbiome composition
no changein humans2
Bifidobacterium breve showed no clear effect on microbiome composition in humans (patients with sarcopenia).
Human trialpatients with sarcopenia2 × 10 10 cells/day24 weeks
Bifidobacterium breve showed no clear effect on microbiome composition in humans.
Human trialprobiotic strain Bifidobacterium breve MCC1274 (A1)24 weeks
Knee extension strength
no changein humans1
1 study
Knee extension strength
no changein humans1
Bifidobacterium breve showed no clear effect on knee extension strength in humans.
Human trial24 weeksn = 50
Skin epithelial damage
downin human cells1
1 study
Skin epithelial damage
downin human cells1
Bifidobacterium breve decreases skin epithelial damage in human cells (skin cleanser-induced skin epithelial damage in ex vivo human skin).
Cellsskin cleanser-induced skin epithelial damage in ex vivo human skinskin
keratinocyte differentiation
upin human cells1
1 study
keratinocyte differentiation
upin human cells1
Bifidobacterium breve activates keratinocyte differentiation in ex vivo human skin.
Cellsin ex vivo human skinskin
Wrinkle depth
downin humans1
1 study
Wrinkle depth
downin humans1
Bifidobacterium breve decreases wrinkle depth in humans.
Review
Brain atrophy
downin humans1
1 study
Brain atrophy
downin humans1
Bifidobacterium breve decreases brain atrophy in humans.
Human trialbrain24 weeksn = 89
Trial sponsors
1 trialEarly phase 15 people